The moonlighting enzyme CD13: old and new functions to target

被引:343
作者
Mina-Osorio, Paola [1 ]
机构
[1] Feinstein Inst Med Res, Autoimmune Dis Ctr, Manhasset, NY 11030 USA
关键词
D O I
10.1016/j.molmed.2008.06.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aminopeptidase N(CD13) is a widely expressed ectoenzyme with functions that do not always depend on its enzymatic activity: an aspect that has been overlooked. Numerous CD13-targeting tools have been developed in the last few years. Several of them are already undergoing clinical trials, and there are promising reports on the effectiveness of others in animal models of disease. However, their efficacy might be obscured by their effects on unrecognized functions of CD13, resulting in unexpected complications. The purpose of this review is (i) to discuss the various functions ascribed to CD13 and the possible mechanisms behind them and (ii) to consider some of the questions that need to be answered to achieve a better understanding of the biological relevance of these functions, a more precise interpretation of the results obtained after their manipulation and a more rational design of CD13-targeting agents.
引用
收藏
页码:361 / 371
页数:11
相关论文
共 112 条
[1]   Structure of aminopepidase N from Escherichia coli suggests a compartmentalized, gated active site [J].
Addlagatta, Anthony ;
Gay, Leslie ;
Matthews, Brian W. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (36) :13339-13344
[2]   Membrane bound members of the M1 family: More than aminopeptidases [J].
Albiston, AL ;
Ye, SY ;
Chai, SY .
PROTEIN AND PEPTIDE LETTERS, 2004, 11 (05) :491-500
[3]   A mutation in aminopeptidase N (CD13) isolated from a patient suffering from leukemia leads to an arrest in the endoplasmic reticulum [J].
Alfalah, M ;
Krahn, MP ;
Wetzel, G ;
von Hörsten, S ;
Wolke, C ;
Hooper, N ;
Kalinski, T ;
Krueger, S ;
Naim, HY ;
Lendeckel, U .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (17) :11894-11900
[4]  
Amoscato AA, 1998, J IMMUNOL, V161, P4023
[5]  
ASHMUN RA, 1992, BLOOD, V79, P3344
[6]   Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) -: A novel approach for the treatment of inflammatory bowel disease [J].
Bank, Ute ;
Heimburg, Anke ;
Helmuth, Martin ;
Stefin, Sofia ;
Lendeckel, Uwe ;
Reinhold, Dirk ;
Faust, Juergen ;
Fuchs, Petra ;
Sens, Bianca ;
Neubert, Klaus ;
Taeger, Michael ;
Ansorge, Siegfried .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2006, 6 (13-14) :1925-1934
[7]   Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects [J].
Bauvois, B ;
Dauzonne, D .
MEDICINAL RESEARCH REVIEWS, 2006, 26 (01) :88-130
[8]   Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? [J].
Bauvois, B .
ONCOGENE, 2004, 23 (02) :317-329
[9]   The bradykinin B2 receptor antagonist icatibant (Hoe 140) blocks aminopeptidase N at micromolar concentrations:: Off-target alterations of signaling mediated by the bradykinin B1 and angiotensin receptors [J].
Bawolak, Marie-Therese ;
Fortin, Jean-Philippe ;
Vogel, Lotte K. ;
Adam, Albert ;
Marceau, Francois .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 551 (1-3) :108-111
[10]   CD13/APN is activated by angiogenic signals and is essential for capillary tube formation [J].
Bhagwat, SV ;
Lahdenranta, J ;
Giordano, R ;
Arap, W ;
Pasqualini, R ;
Shapiro, LH .
BLOOD, 2001, 97 (03) :652-659